Literature DB >> 17038709

BCG vaccine effectiveness against Buruli ulcer: a case-control study in Benin.

Fabienne Nackers1, Michèle Dramaix, Roch Christian Johnson, Claude Zinsou, Annie Robert, Elisa DE Biurrun Bakedano, Judith R Glynn, Françoise Portaels, René Tonglet.   

Abstract

BCG remains the only possible prophylactic intervention against Buruli ulcer (BU). Estimating its public health impact on BU control is an important issue. We conducted a case-control study to investigate the vaccine effectiveness of routine BCG vaccine against BU in southern Benin. From August 2002 to August 2003, BCG vaccination status was obtained for 279 clinically diagnosed BU cases and 988 age- and sex-matched neighborhood controls. BCG coverage, which was estimated by the presence of a scar or a vaccination record, was 64.5% in cases and 67.2% in controls. There was no evidence of a protective effect of routine BCG vaccination against BU in southern Benin (vaccine effectiveness adjusted for socioeconomic status = 12%, 95% confidence interval = -24% to 37%).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17038709

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  17 in total

1.  Integrative immunoinformatics for Mycobacterial diseases in R platform.

Authors:  Rupanjali Chaudhuri; Deepika Kulshreshtha; Muthukurussi Varieth Raghunandanan; Srinivasan Ramachandran
Journal:  Syst Synth Biol       Date:  2014-02-15

2.  Systemic and local interferon-gamma production following Mycobacterium ulcerans infection.

Authors:  H S Schipper; B Rutgers; M G Huitema; S N Etuaful; B D Westenbrink; P C Limburg; W Timens; T S van der Werf
Journal:  Clin Exp Immunol       Date:  2007-09-27       Impact factor: 4.330

3.  BCG-mediated protection against Mycobacterium ulcerans infection in the mouse.

Authors:  Paul J Converse; Deepak V Almeida; Eric L Nuermberger; Jacques H Grosset
Journal:  PLoS Negl Trop Dis       Date:  2011-03-15

4.  Protection against Mycobacterium ulcerans lesion development by exposure to aquatic insect saliva.

Authors:  Laurent Marsollier; Estelle Deniaux; Priscille Brodin; Agnès Marot; Christelle Mbondji Wondje; Jean-Paul Saint-André; Annick Chauty; Christian Johnson; Fredj Tekaia; Edouard Yeramian; Pierre Legras; Bernard Carbonnelle; Gilles Reysset; Sara Eyangoh; Geneviève Milon; Stewart T Cole; Jacques Aubry
Journal:  PLoS Med       Date:  2007-02       Impact factor: 11.069

5.  Recombinant BCG Expressing Mycobacterium ulcerans Ag85A Imparts Enhanced Protection against Experimental Buruli ulcer.

Authors:  Bryan E Hart; Laura P Hale; Sunhee Lee
Journal:  PLoS Negl Trop Dis       Date:  2015-09-22

6.  Use of Recombinant Virus Replicon Particles for Vaccination against Mycobacterium ulcerans Disease.

Authors:  Miriam Bolz; Sarah Kerber; Gert Zimmer; Gerd Pluschke
Journal:  PLoS Negl Trop Dis       Date:  2015-08-14

7.  Risk factors for buruli ulcer in Ghana-a case control study in the Suhum-Kraboa-Coaltar and Akuapem South Districts of the eastern region.

Authors:  Ernest Kenu; Kofi Mensah Nyarko; Linda Seefeld; Vincent Ganu; Michael Käser; Margaret Lartey; Benedict Nii Laryea Calys-Tagoe; Kwodwo Koram; Richard Adanu; Oliver Razum; Edwin Afari; Fred N Binka
Journal:  PLoS Negl Trop Dis       Date:  2014-11-20

8.  Risk factors for Buruli ulcer, Benin.

Authors:  Martine Debacker; Frangoise Portaels; Julia Aguiar; Christian Steunou; Claude Zinsou; Wayne Meyers; Michèle Dramaix
Journal:  Emerg Infect Dis       Date:  2006-09       Impact factor: 6.883

9.  Improved protective efficacy of a species-specific DNA vaccine encoding mycolyl-transferase Ag85A from Mycobacterium ulcerans by homologous protein boosting.

Authors:  Audrey Tanghe; Jean-Pierre Dangy; Gerd Pluschke; Kris Huygen
Journal:  PLoS Negl Trop Dis       Date:  2008-03-19

10.  Risk factors for buruli ulcer: a case control study in Cameroon.

Authors:  Régis Pouillot; Gonçalo Matias; Christelle Mbondji Wondje; Françoise Portaels; Nadia Valin; François Ngos; Adelaïde Njikap; Laurent Marsollier; Arnaud Fontanet; Sara Eyangoh
Journal:  PLoS Negl Trop Dis       Date:  2007-12-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.